be maximized prior to increasing systemic immunosuppressive therapy. Although no direct comparative data are available, mepolizumab was found to be efficacious in a randomized trial in patients specifically described in this recommendation: those with relapsing nonsevere EGPA who are receiving immunosuppressive therapy Recommendation: For patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving low-dose